C-type natriuretic peptide in combination with sildenafil attenuates proliferation of rhabdomyosarcoma cells

Cancer Medicine

Volumn 5, Issue 5, 2016, Pages 795-805

  Zenitani, Masahiro ^a,b   Nojiri, Takashi ^a   Uehara, Shuichiro ^b   Miura, Koichi ^a   Hosoda, Hiroshi ^a   Kimura, Toru ^a   Nakahata, Kengo ^b   Miyazato, Mikiya ^a   Okuyama, Hiroomi ^b   Kangawa, Kenji ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiproliferation; cGMP; CNP; ERK; PDE5 inhibitor

Indexed keywords

CYCLIC GMP; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NATRIURETIC PEPTIDE RECEPTOR B; NATRIURETIC PEPTIDE TYPE C; PHOSPHODIESTERASE; RAF PROTEIN; SILDENAFIL; ANTINEOPLASTIC AGENT; ATRIAL NATRIURETIC FACTOR RECEPTOR;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CHILD; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INFANT; MALE; MOUSE; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; RHABDOMYOSARCOMA CELL; SCHOOL CHILD; SIGNAL TRANSDUCTION; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; ENZYMOLOGY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROCEDURES; TUMOR CELL CULTURE; UPREGULATION;

ADOLESCENT; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; INFANT; MALE; MAP KINASE SIGNALING SYSTEM; MICE, INBRED BALB C; NATRIURETIC PEPTIDE, C-TYPE; PHOSPHORYLATION; RECEPTORS, ATRIAL NATRIURETIC FACTOR; RHABDOMYOSARCOMA; SILDENAFIL CITRATE; TUMOR CELLS, CULTURED; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85006228099     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.642     Document Type: Article

References (41)

1. Crist, W. M., and L. E. Kun . 1991. Common solid tumors of childhood. N. Engl. J. Med. 324:461-471.
2. Ognjanovic, S., A. M. Linabery, B. Charbonneau, and J. A. Ross . 2009. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer 115:4218-4226.
3. Sudoh, T., N. Minamino, K. Kangawa, and H. Matsuo . 1990. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem. Biophys. Res. Commun. 168:863-870.
4. Furuya, M., M. Yoshida, Y. Hayashi, N. Ohnuma, N. Minamino, and K. Kangawa . 1991. C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 177:927-931.
5. Hutchinson, H. G., P. T. Trindade, D. B. Cunanan, C. F. Wu, and R. E. Pratt . 1997. Mechanisms of natriuretic-peptide-induced growth inhibition of vascular smooth muscle cells. Cardiovasc. Res. 35:158-167.
6. Canaan-Kühl, S., T. Ostendorf, K. Zander, K. M. Koch, and J. Floege . 1998. C-type natriuretic peptide inhibits mesangial cell proliferation and matrix accumulation in vivo. Kidney Int. 53:1143-1151.
7. Osawa, H., H. Yamabe, M. Kaizuka, N. Tamura, S. Tsunoda, and Y. Baba . 2000. C-type natriuretic peptide inhibits proliferation and monocyte chemoattractant protein-1 secretion in cultured human mesangial cells. Nephron 86:467-472.
8. Segawa, K., K. Minami, N. Jimi, Y. Nakashima, and A. Shigematsu . 1998. C-type natriuretic peptide inhibits rat mesangial cell proliferation by a phosphorylation-dependent mechanism. Naunyn-Schmiederberg's Arch. Pharmacol. 357:70-76.
9. Soeki, T., I. Kishimoto, H. Okumura, T. Tokudome, T. Horio, K. Mori, et al. 2005. C-Type natriuretic peptide, a novel antifibrotic and antihypertrophic agent prevents cardiac remodeling after myocardial infarction. J. Am. Coll. Cardiol. 45:608-616.
10. Chrisman, T. D., and D. L. Garbers . 1999. Reciprocal antagonism coordinates C-type natriuretic peptide and mitogen-signaling pathways in fibroblasts. J. Biol. Chem. 274:4293-4299.
11. Langenickel, T. H., J. Buttgereit, I. Pagel-Langenickel, M. Lindner, J. Monti, K. Beuerlein, et al. 2006. Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B. Proc. Natl Acad. Sci. USA 103:4735-4740.
12. Padma-Nathan, H., W. D. Steers, and P. A. Wicker . 1998. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Sildenafil Study Group. Int. J. Clin. Pract. 52:375-379.
13. Barst, R. J., D. D. Ivy, G. Gaitan, A. Szatmari, A. Rudzinski, A. E. Garcia, et al. 2012. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 125:324-334.
14. Kimura, T., T. Nojiri, H. Hosoda, S. Ishikane, Y. Shintani, M. Inoue, et al. 2015a. C-type natriuretic peptide attenuates LPS-induced acute lung injury in mice. J. Surg. Res. 194:631-637.
15. Suga, S., K. Nakao, I. Kishimoto, K. Hosoda, M. Mukoyama, H. Arai, et al. 1992. Phenotype-related alteration in expression of natriuretic peptide receptors in aortic smooth muscle cells. Circ. Res. 71:34-39.
16. Kaneki, H., M. Kurokawa, and H. Ide . 2008. The receptor attributable to C-type natriuretic peptide-induced differentiation of osteoblasts is switched from type B- to type C-natriuretic peptide receptor with aging. J. Cell. Biochem. 103:753-764.
17. Sang, L., H. A. Coller, and J. M. Roberts . 2008. Control of the reversibility of cellular quiescence by the transcriptional repressor HES1. Science 321:1095-1100.
18. Belyea, B. C., S. Naini, R. C. Bentley, and C. M. Linardic . 2011. Inhibition of the notch-hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis. Clin. Cancer Res. 17:7324-7336.
19. Zeng, F. Y., H. Dong, J. Cui, L. Liu, and T. Chen . 2010. Glycogen synthase kinase 3 regulates PAX3-FKHR-mediated cell proliferation in human alveolar rhabdomyosarcoma cells. Biochem. Biophys. Res. Commun. 391:1049-1055.
20. Tostar, U., R. Toftgård, P. G. Zaphiropoulos, and T. Shimokawa . 2010. Reduction of human embryonal rhabdomyosarcoma tumor growth by inhibition of the hedgehog signaling pathway. Genes Cancer 1:941-951.
21. Cen, L., F. C. Hsieh, H. J. Lin, C. S. Chen, S. J. Qualman, and J. Lin . 2007. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound. Br. J. Cancer 97:785-791.
22. Petricoin, E. F., V. Espina, R. P. Araujo, B. Midura, C. Yeung, X. Wan, et al. 2007. Phosphoprotein pathway mapping: akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 67:3431-3440.
23. Ciccarelli, C., F. Marampon, A. Scoglio, A. Mauro, C. Giacinti, P. De Cesaris, et al. 2005. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells. Mol. Cancer. 4:41.
24. Marampon, F., G. Bossi, C. Ciccarelli, A. Di Rocco, A. Sacchi, R. G. Pestell, et al. 2009. MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma. Mol. Cancer Ther. 8:543-551.
25. Kumazoe, M., K. Sugihara, S. Tsukamoto, Y. Huang, Y. Tsurudome, T. Suzuki, et al. 2013. 67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis. J. Clin. Invest. 123:787-799.
26. Li, N., Y. Xi, H. N. Tinsley, E. Gurpinar, B. D. Gary, B. Zhu, et al. 2013. Sulindac selectively inhibits colon tumor cell growth by activating the cgmp/pkg pathway to suppress wnt/b-catenin signaling. Mol. Cancer Ther. 12:1848-1859.
27. Hagiwara, H., A. Inoue, M. Furuya, S. Tanaka, and S. Hirose . 1996. Change in the expression of C-type natriuretic peptide and its receptor, B-type natriuretic peptide receptor, during dedifferentiation of chondrocytes into fibroblast-like cells. J. Biochem. 119:264-267.
28. Schaaf, G., M. Hamdi, D. Zwijnenburg, A. Lakeman, D. Geerts, R. Versteeg, et al. 2010. Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene. Cancer Res. 70:762-771.
29. Chardin, P., P. Yeramian, P. Madaule, and A. Tavitian . 1985. N-ras gene activation in the RD human rhabdomyosarcoma cell line. Int. J. Cancer 35:647-652.
30. Stratton, M. R., C. Fisher, B. A. Gusterson, and C. S. Cooper . 1989. Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res. 49:6324-6327.
31. Krejci, P., B. Masri, V. Fontaine, P. B. Mekikian, M. Weis, H. Prats, et al. 2005. Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J. Cell Sci. 118:5089-5100.
32. Suhasini, M., H. Li, S. M. Lohmann, G. R. Boss, and R. B. Pilz . 1998. Cyclic-GMP-dependent protein kinase inhibits the Ras/Mitogen-activated protein kinase pathway. Mol. Cell. Biol. 18:6983-6994.
33. Itoh, T., N. Nagaya, S. Murakami, T. Fujii, T. Iwase, H. Ishibashi Ueda, et al. 2004. C-type natriuretic peptide ameliorates monocrotaline-induced pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 170:1204-1211.
34. Obata, H., B. Yanagawa, K. Tanaka, S. Ohnishi, M. Kataoka, Y. Miyahara, et al. 2007. CNP infusion attenuates cardiac dysfunction and inflammation in myocarditis. Biochem. Biophys. Res. Commun. 356:60-66.
35. Schachner, T., Y. Zou, A. Oberhuber, T. Mairinger, A. Tzankov, G. Laufer, et al. 2004. Perivascular application of C-type natriuretic peptide attenuates neointimal hyperplasia in experimental vein grafts. Eur. J. Cardiothorac. Surg. 25:585-590.
36. Kimura, T., T. Nojiri, H. Hosoda, S. Ishikane, Y. Shintani, M. Inoue, et al. 2015b. Protective effects of C-type natriuretic peptide on cisplatin-induced nephrotoxicity in Mice. Cancer Chemother. Pharmacol. 75:1057-1063.
37. Siehr, S. L., E. K. McCarthy, M. T. Ogawa, and J. A. Feinstein . 2015. Reported sildenafil side effects in pediatric pulmonary hypertension patients. Front. Pediatr. 3:12.
38. Sabri, M. R., and E. Beheshtian . 2014. Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension. Pediatr. Cardiol. 35:699-704.
39. Nojiri, T., H. Hosoda, T. Tokudome, K. Miura, S. Ishikane, K. Otani, et al. 2015. Atrial natriuretic peptide prevents cancer metastasis through vascular endothelial cells. Proc. Natl Acad. Sci. USA 112:4086-4091.
40. Del Ry, S. 2013. C-type natriuretic peptide: a new cardiac mediator. Peptides 40:93.
41. Yasoda, A., and K. Nakao . 2010. Translational research of C-type natriuretic peptide (CNP) into skeletal dysplasias. Endocr. J. 57:659-666.